{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-006832","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.819919+00:00","generated_at":"2026-05-25T00:45:47.036399+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CervoMed announces positive Phase 2b extension results for neflamapimod in DLB","bullets":["New capsule batch yielded higher plasma levels; CDR-SB improved vs old capsules (p<0.001) and vs placebo (p=0.003).","CGIC score improved with new capsules vs old (4.02 vs 4.46, p=0.035); within-subject placebo comparison also significant (p=0.035).","Fall incidence lower with new capsules (7.4%) vs old (14.5%) and vs placebo (18.8%, p=0.04); in ptau181 <2.2 subgroup: 4.0% vs 19.7% (p=0.007).","149 patients entered extension; 94 received new capsules; completion rates 87.3% (old) and 91.5% (new); no new safety signals.","Company plans to complete full 32-week extension and discuss Phase 3 plans with regulators later this year."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-006832","json":"https://secwatch.observer/filing/0001437749-25-006832.json","markdown":"https://secwatch.observer/filing/0001437749-25-006832.md","text":"https://secwatch.observer/filing/0001437749-25-006832.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925006832/0001437749-25-006832-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925006832/crvo20250310_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T00:45:47.036399+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}